29 completed, 4 terminated, 2 unknown, 1 recruiting. 37 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 37 | Completed 29, Terminated 4, Unknown 2, Recruiting 1, Withdrawn 1 |
Follow LEO Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares Spesolimab - Generalized Pustular Psoriasis | Phase 4 | Completed | LEO Pharma | 42 | 2023-10-22 | 2026-10-26 |
| Tralokinumab for Dupilumab Failures tralokinumab - Atopic Dermatitis | Phase 4 | Terminated | Psoriasis Treatment Center of Central New Jersey | 7 | 2023-09-11 | 2026-05-22 |
| Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight Brodalumab - Psoriasis Vulgaris | Phase 4 | Completed | LEO Pharma | 385 | 2022-07-21 | 2026-04-24 |
| Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome tinzaparin, Rivaroxaban - Deep Vein Thrombosis, Post Thrombotic Syndrome | Phase 4 | Terminated | Sunnybrook Health Sciences Centre | 9 | 2021-11-15 | 2024-04-04 |
| A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis Enstilar Foam - Nail Psoriasis | Phase 4 | Completed | University of Alabama at Birmingham | 6 | 2021-11-01 | 2025-01-17 |
| Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab Brodalumab, Placebo, Guselkumab - Plaque Psoriasis, Psoriasis Vulgaris | Phase 4 | Terminated | LEO Pharma | 113 | 2020-12-17 | 2025-03-14 |
| The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover Betnovate, betamethasone dipropionate ointment 0.1% and placebo, Protopic, tacrolimus ointment 0.1% - Atopic Dermatitis, Atopic Eczema | Phase 4 | Completed | Jacob Thyssen | 36 | 2019-08-22 | 2021-04-28 |
| Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis Enstilar 0.005%-0.064% Topical Foam - Psoriasis | Phase 4 | Recruiting | Psoriasis Treatment Center of Central New Jersey | 30 | 2019-01-16 | 2019-02-04 |
| Investigation of Flare and Remission in Subjects With Atopic Dermatitis Cyclosporine A - Atopic Dermatitis | Phase 4 | Withdrawn | LEO Pharma | 2019-01-14 | 2024-11-07 | |
| Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis Brodalumab, Placebos - Psoriasis | Phase 4 | Unknown | Aarhus University Hospital | 50 | 2018-09-15 | 2019-07-10 |
| A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Brodalumab, Fumaric acid esters - Psoriasis Vulgaris | Phase 4 | Completed | LEO Pharma | 210 | 2017-11-03 | 2025-03-13 |
| Enstilar in Combination With Biologic Agents Enstilar 0.005%-0.064% Topical Foam - Psoriasis | Phase 4 | Completed | Psoriasis Treatment Center of Central New Jersey | 25 | 2017-05-01 | 2018-01-03 |
| Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Xamiol® gel, Daivonex® scalp solution - Psoriasis Vulgaris | Phase 4 | Completed | LEO Pharma | 951 | 2015-09-01 | 2025-02-24 |
| Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Ingenol Mebutate Gel, 0.015%, Diclofenac sodium gel 3% - Actinic Keratosis (AK) | Phase 4 | Completed | LEO Pharma | 502 | 2015-04-01 | 2025-02-24 |
| Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis ingenol mebutate gel 0.015%, ingenol mebutate gel 0.05% - Actinic Keratosis | Phase 4 | Completed | Korea University | 77 | 2015-04-01 | 2018-04-18 |
| Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% Inggenol Mebutate 0.015% - Actinic Keratosis | Phase 4 | Completed | Goldman, Butterwick, Fitzpatrick and Groff | 21 | 2015-01-01 | 2019-09-06 |
| Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Ingenol Mebutate Gel, 0.015%, Imiquimod Cream, 5% - Actinic Keratosis (AK) | Phase 4 | Completed | LEO Pharma | 485 | 2013-09-11 | 2025-03-07 |
| Use of Tinzaparin for Anticoagulation in Hemodialysis Tinzaparin, Unfractionated Heparin, Placebo (for Tinzaparin) - Kidney Failure, Chronic | Phase 4 | Completed | Christine Ribic | 191 | 2013-09-01 | 2016-10-14 |
| Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Ingenol Mebutate, Cryotherapy - Actinic Keratoses | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 16 | 2013-04-01 | 2017-04-26 |
| A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy Taclonex Topical Suspension - Psoriasis | Phase 4 | Completed | University of Pittsburgh | 8 | 2013-01-01 | 2016-09-21 |
Showing 20 of 37. Sign in to see all of them.
Psoriasis (6) · Keratosis, Actinic (5) · Dermatitis, Atopic (4) · Venous Thrombosis (4) · Thrombosis (3) · Venous Thromboembolism (3) · Rosacea (2) · Thromboembolism (2) · Birth Weight (1) · Breast Neoplasms (1) · Dermatitis, Contact (1) · Dermatitis, Irritant (1) · Dermatitis, Occupational (1) · Fetal Growth Retardation (1) · Fractures, Bone (1)
Tinzaparin (9) · betamethasone dipropionate, calcipotriol drug combination (4) · brodalumab (4) · 3-ingenyl angelate (3) · calcipotriene (3) · Acenocoumarol (2) · Heparin (2) · Tacrolimus (2) · acarboxyprothrombin (2) · azelaic acid (2) · Betamethasone (1) · Betamethasone Valerate (1) · Clobetasol (1) · Cryotherapy (1) · Cyclosporine (1)
Germany (10) · United States (10) · Spain (8) · Denmark (7) · France (7) · Canada (6) · Netherlands (5) · United Kingdom (5) · Belgium (4) · Italy (4) · China (3) · Sweden (3) · Czechia (2) · Greece (2) · Poland (2)
Russell D Hull, MBBS, MSc (2) · Adele R Clark, PA-C (1) · Alain Leizorovicz, MD (1) · Alan B Fleischer, Jr, M.D. (1) · Alejandro Veres Racamonde, MD (1) · Anders Clemmensen, MD (1) · Anne-Mette Hvas, PhD, professor (1) · Antoni Romera, MD (1) · Boni E Elewski, Dr (1) · David Sam, M.D. FRCPC (1) · Dr. Christine M Ribic, MD, MSc (1) · Eggert Stockfleth, Prof.Dr.med. (1)
PMID 10607349, PMID 11063900, PMID 15097955, PMID 17822489, PMID 18955209, PMID 19467365, PMID 20514316, PMID 20645521, PMID 21477846, PMID 21753882, PMID 22055282, PMID 22417254, PMID 22714759, PMID 23048011, PMID 23245654, PMID 23510990, PMID 23553119, PMID 24446656, PMID 24892649, PMID 27462386, PMID 27672408, PMID 28301043, PMID 28979661, PMID 29030864, PMID 36824052, PMID 37907305, PMID 38189593, PMID 38300408, PMID 42126851, PMID 8918873, PMID 9092763, PMID 9627707
2004 (1), 2008 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1)